6-mercaptopurine versus comparator
| 6-Mercaptopurine | Placebo | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| 6-Mercaptopurine versus placebo (all contexts) | 2 | 221 | 1 | 194 | 1.32 (0.16 to 11.05) p=0.80 |
| 6-Mercaptopurine versus placebo (active disease—medical) | 1 | 46 | 0 | 42 | 2.35 (0.09 to 62.09) p=0.61 |
| 6-Mercaptopurine versus placebo (maintenance of remission—medical) | – | – | – | – | – |
| 6-Mercaptopurine versus placebo (maintenance of remission—surgical) | 1 | 175 | 1 | 52 | 0.87 (0.05 to 14.14) p=0.92 |
| 6-Mercaptopurine | Mesalazine | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| 6-Mercaptopurine versus mesalazine (all contexts) | 0 | 47 | 0 | 44 | – |
| 6-Mercaptopurine versus mesalazine (active disease—medical) | – | – | – | – | |
| 6-Mercaptopurine versus mesalazine (maintenance of remission—medical) | – | – | – | – | |
| 6-Mercaptopurine versus mesalazine (maintenance of remission—surgical) | 0 | 47 | 0 | 44 | – |
Incidence of pancreatitis.